Comparative Pharmacology
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE 65 versus SYNALGOS DC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE 65 versus SYNALGOS DC.
PROPOXYPHENE HYDROCHLORIDE 65 vs SYNALGOS-DC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a centrally acting opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting pain signal transmission and altering pain perception. It also has local anesthetic effects.
Dihydrocodeine is a semisynthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception. Aspirin inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby providing analgesic and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia by reducing pain perception and increasing the efficacy of other analgesics.
65 mg orally every 4 hours as needed for pain; maximum 390 mg/day.
1-2 capsules orally every 4 hours as needed for pain; each capsule contains dihydrocodeine bitartrate 16 mg, acetaminophen 356.4 mg, and caffeine 30 mg. Maximum: 8 capsules per day.
None Documented
None Documented
6-12 hours (mean ~8 hours); prolonged in hepatic impairment and elderly; accumulation possible with repeated dosing.
Dihydrocodeine: 3.5-4.5 hours; aspirin: 15-20 minutes; caffeine: 3-6 hours. Context: Dihydrocodeine half-life supports q4-6h dosing; aspirin short half-life limits analgesia duration.
Renal excretion of unchanged drug (approximately 20-30%) and metabolites; approximately 40-60% as conjugated metabolites; minor biliary/fecal elimination.
Renal: ~90% (dihydrocodeine, as metabolites, primarily glucuronides); biliary/fecal: ~10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic